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Abstract
Our group and others have determined that immune effector cells from patients with advanced cancers exhibit reduced activation of IFN signaling pathways. We hypothesized that increases in immune regulatory cells termed myeloid derived suppressor cells (MDSC) could interfere with the host immune response to tumors by inhibiting immune cell responsiveness to interferons. The C26 murine adenocarcinoma model was employed to study immune function in advanced malignancy. C26 bearing mice had significantly elevated levels of GR1+CD11b+ MDSC as compared to control mice, and splenocytes from tumor bearing mice exhibited reduced phosphorylation of STAT1 (P-STAT1) on 
Introduction
Previous studies demonstrated that the endogenous production of interferon is essential for immunosurveillance against developing tumors (1, 2) . It has been determined that mice lacking either the IFNγ receptor (IFNγR1) or the major IFN signal transducer STAT1, developed tumors at a faster rate than wild type mice following exposure to the (6) . These cells arise from myeloid precursors in 4 response to tumor-derived growth factors and pro-inflammatory cytokines (6, 7). MDSC are described phenotypically in murine models as GR1 + CD11b + , with subsets expressing IL-4Rα (7, 8) . MDSC have been shown to reside in the peripheral blood, lymphoid tissue, and tumor tissue of mice in a number of experimental models (6, (9) (10) (11) (12) (13) . Prior studies have demonstrated that MDSC can inhibit the effector function of NK and T cells in tumor-bearing animals through multiple mechanisms, including the release of immunesuppressive cytokines, the generation of nitric oxide and reactive oxygen species, and the depletion of arginine or cystine from the tumor microenvironment (6, 14, 15) . Studies in murine models indicate that disruption of MDSC function can reverse immune tolerance to tumor antigens, stimulate anti-tumor immune responses and markedly inhibit tumor growth (6, 7).
We hypothesized that elevated numbers of MDSC present in the setting of advanced malignancy would inhibit the response of immune cells to type I and II interferons. The results of our experiments demonstrated that mice bearing C26 adenocarcinoma tumors exhibit elevated numbers of MDSC which led to increased nitration on STAT1 and impaired responsiveness of immune effector cells to interferons. isotype control antibody (4, 17, 18) . CD4, CD8, and CD49b antibodies were used for surface staining of immune subsets (BD Biosciences). For nitration flow cytometry, splenocytes were co-labeled with anti-STAT1-PE and anti-nitrotyrosine-alexafluor-488
Methods.

Cytokines and
antibody (BD Biosciences and Millipore).
Real Time PCR. Following TRIzol extraction (Invitrogen) and RNeasy purification (Qiagen), total RNA was quantitated and reverse transcribed as previously described (19 
Statistical Analysis.
Two-sample t-tests were used to compare outcomes (e.g. IL-6, Ifit2, P-STAT1) between groups. If necessary, outcomes were log-transformed to meet the assumptions of normality and constant variance for the test. Pearson correlation coefficients were used to quantify the relationship between outcomes. Tumor growth was assumed to be log-linear and a mixed effects model with a random intercept and slope for each animal was used to estimate the rate of increase. P-values less than 0.05 were considered statistically significant. 
Results
Decreased interferon response of immune cells from tumor-bearing mice.
We hypothesized that immune effector cells in tumor-bearing mice would have an altered response to cytokines that promote anti-tumor immunity as is seen in patients with advanced malignancy. Of particular interest were the type I and type II IFNs, as these cytokines mediate tumor immunosurveillance, and reductions in immune cell IFN responsiveness have been shown to exist in cancer patients (1) (2) (3) 24 ). The C26 model was chosen for this study due to its rapid tumor growth and ability to mimic advanced 
Reduction of MDSC leads to restored IFN-responsiveness in C26-bearing mice.
C26-bearing animals were treated with the drug gemcitabine, a nucleoside analog, which has been previously employed by other groups to deplete MDSC (20) (21) (22) 26 GR1+CD11b+ MDSC were also evaluated in the tumor after treatment with gemcitabine or anti-GR1. All treatments led to a reduction in intra-tumor MDSC as compared to tumor-bearing control animals (Supplemental Figure 5) . 
Elevated nitric oxide and IFN-responsiveness. We hypothesized that soluble factors produced from the abundant MDSC present in the splenic tissue could contribute to the reduced IFN-response in tumor-bearing mice. We evaluated two of the major mechanisms through which MDSC are known to exert their suppressive effects, and discovered that while arginase I transcript levels were not significantly different in tumorbearing splenocytes as compared to splenocytes from normal mice, iNOS mRNA levels were dramatically elevated (data not shown and Supplemental Figure 3C ). DAF-FM and iNOS staining and fluorescent microscopic analysis were employed to test whether decreased IFN-responsiveness might be associated with increased levels of NO in the splenic tissue. These data confirmed a dramatic increase in the level of iNOS protein and NO in splenocytes from C26-bearing mice as compared to spleens from control animals Student's t-test analysis on the densitometry results and determined that the ratio of nitrated STAT1 to total STAT1 in tumor bearing mice is statistically higher than in normal mice, demonstrating that C26-bearing animals exhibited significantly elevated nitration of STAT1 as compared to control mice (p=0.03; Figure 5C ). In addition, we CAN-10-2670 led to increased nitration of tyrosine residues, which inhibited transcription factor phosphorylation following CD3 stimulation, while Llovera et al. showed that LPS-treated macrophages had an impaired in vitro immune cell response to IFN-γ due to an increase in nitric oxide in the culture (28, 29) . We observed that tumor-bearing mice exhibited elevated splenic levels of iNOS protein and treatment of normal splenocytes with SNAP, a nitric oxide donor, suppressed the P-STAT1 response of the splenocytes to IFN-Į stimulation. Nitration on STAT1 in primary lymphocytes from tumor-bearing mice has not previously been demonstrated in an in vivo murine model. These findings support a role for nitric oxide in the inhibition of IFN signal transduction.
In the studies with iNOS-deficient mice, interferon responsiveness in splenocytes from tumor-bearing animals was not fully restored to levels observed in normal animals. This indicates that other mechanisms may exert an effect on the interferon response in the tumor microenvironment. We evaluated alternative mechanisms that could lead to this inhibition, such as increased levels of arginase I or IL-6. Up-regulation of arginase I has been identified as a mechanism of immune suppression that is employed by MDSC (30) (31) (32) . While previous studies in macrophages have demonstrated an inverse relationship between iNOS and arginase I levels, it has been shown that in a tumor setting it is possible for iNOS and Arg I to be co-expressed (8, 20, 33, 34) . However, splenic levels of this enzyme were not significantly elevated in the C26 model. While arginase could still be playing a role in the tumor environment, our data in iNOS-deficient mice suggests that iNOS is a driving factor for the decreased IFN response in immune cells in this 
